Aslan starts Phase IIb trial of atopic dermatitis IL-13 antibody
The trial is expected to enrol subjects across 100 sites in North America, Asia Pacific and Europe.
Europe
Latest in
Europe
Signant to serve as technology vendor for Trials@Home consortium
The research project is funded by the EU/EFPIA’s Innovative Medicines Initiative Joint Undertaking.
UNION’s orismilast enters Phase IIb and a crowded small molecule market
If approved, orismilast would be the second oral phosphodiesterase-4 inhibitor to enter the plaque psoriasis space.
By
Sensorion’s sudden sensorineural hearing loss asset fails Phase II test
The asset failed to meet the primary goal of 15 decibels, a substantial improvement in pure tone audiometry in the…
Mapping Endpoints: How to build an ALS clinical trial
Differing endpoint and efficacy expectations can make designing an ALS clinical trial challenging. Clinical Trials Arena looks at ways to…
By
Phio Pharmaceuticals obtains clearance for melanoma treatment trial
The dosing of the first subject in the Phase Ib trial of PH-762 is anticipated to begin in the first…
ALS: drug trial results to watch in 2022
Pharma companies are pouring more efforts into ALS studies, setting the stage for several major drug trial readouts this year.
By
UNION therapeutics begins enrolment in trial of orismilast for psoriasis
The Phase IIb study will assess orismilast’s safety and efficacy in patients with moderate to severe plaque psoriasis.
By